nach oben

Erschienen in:

08.12.2015 | Review Article

Review: circulating tumor cells in the practice of breast cancer oncology

verfasst von: R. Ramos-Medina, F. Moreno, S. Lopez-Tarruella, M. del Monte-Millán, I. Márquez-Rodas, E. Durán, Y. Jerez, J. A. Garcia-Saenz, I. Ocaña, S. Andrés, T. Massarrah, M. González-Rivera, M. Martin

Erschienen in: Clinical and Translational Oncology | Ausgabe 8/2016

Einloggen, um Zugang zu erhalten

Abstract

The primary cause of tumor-related death in breast cancer is still represented by distant metastasization. The dissemination of tumor cells from the primary tumor to distant sites through bloodstream cannot be early detected by standard imaging methods. Circulating tumor cells (CTCs) play a major role in the metastatic spread of breast cancer. Different analytical systems for CTCs isolation and detection have been developed and novel areas of research are directed towards developing assays for CTCs molecular characterization. This review describes the current state of art on CTCs detection techniques and the present and future clinical implications of CTCs enumeration and characterization.

Friel AM, Corcoran C, Crown J, O’Driscoll L. Relevance of circulating tumor cells, extracellular nucleic acids, and exosomes in breast cancer. Breast Cancer Res Treat. 2010;123:613–25.CrossRefPubMed

Liberko M, Kolostova K, Bobek V. Essentials of circulating tumor cells for clinical research and practice. Crit Rev Oncol Hematol. 2013;88:338–56.CrossRefPubMed

De Wit S, van Dalum G, Terstappen LWMM. Detection of circulating tumor cells. Scientifica. 2014;2014:819362.PubMedPubMedCentral

Broersen LHA, van Pelt GW, Tollenaar RAEM, Mesker WE. Clinical application of circulating tumor cells in breast cancer. Cell Oncol Dordr. 2014;37:9–15.CrossRefPubMed

Esmaeilsabzali H, Beischlag TV, Cox ME, Parameswaran AM, Park EJ. Detection and isolation of circulating tumor cells: principles and methods. Biotechnol Adv. 2013;31:1063–84.CrossRefPubMed

Lowes LE, Goodale D, Keeney M, Allan AL. Image cytometry analysis of circulating tumor cells. Methods Cell Biol. 2011;102:261–90.CrossRefPubMed

Alix-Panabières C, Schwarzenbach H, Pantel K. Circulating tumor cells and circulating tumor DNA. Annu Rev Med. 2012;63:199–215.CrossRefPubMed

Ignatiadis M, Riethdorf S, Bidard F-C, Vaucher I, Khazour M, Rothé F, et al. International study on inter-reader variability for circulating tumor cells in breast cancer. Breast Cancer Res. 2014;16:R43.CrossRefPubMedPubMedCentral

Toss A, Mu Z, Fernandez S, Cristofanilli M. CTC enumeration and characterization: moving toward personalized medicine. Ann Transl Med. 2014;2:108.PubMedPubMedCentral

10.

Harouaka R, Kang Z, Zheng S-Y, Cao L. Circulating tumor cells: advances in isolation and analysis, and challenges for clinical applications. Pharmacol Ther. 2014;141:209–21.CrossRefPubMed

11.

Rodrıguez-Gonzalez FG, Mustafa DAM, Mostert B, Sieuwerts AM. The challenge of gene expression profiling in heterogeneous clinical samples. Methods San Diego Calif. 2013;59:47–58.CrossRef

12.

Ghersevich S, Ceballos MP. Mammaglobin A: review and clinical utility. Adv Clin Chem. 2014;64:241–68.CrossRefPubMed

13.

López-Muñoz E, Méndez-Montes M. Markers of circulating breast cancer cells. Adv Clin Chem. 2013;61:175–224.CrossRefPubMed

14.

Gascoyne PRC, Noshari J, Anderson TJ, Becker FF. Isolation of rare cells from cell mixtures by dielectrophoresis. Electrophoresis. 2009;30:1388–98.CrossRefPubMedPubMedCentral

15.

Ozkumur E, Shah AM, Ciciliano JC, Emmink BL, Miyamoto DT, Brachtel E, et al. Inertial focusing for tumor antigen-dependent and -independent sorting of rare circulating tumor cells. Sci Transl Med. 2013;5:179ra47.CrossRefPubMedPubMedCentral

16.

Aurilio G, Sciandivasci A, Munzone E, Sandri MT, Zorzino L, Cassatella MC, et al. Prognostic value of circulating tumor cells in primary and metastatic breast cancer. Expert Rev Anticancer Ther. 2012;12:203–14.CrossRefPubMed

17.

Lianidou ES, Markou A. Circulating tumor cells as emerging tumor biomarkers in breast cancer. Clin Chem Lab Med CCLM FESCC. 2011;49:1579–90.

18.

Harb W, Fan A, Tran T, Danila DC, Keys D, Schwartz M, et al. Mutational analysis of circulating tumor cells using a novel microfluidic collection device and qPCR assay. Transl Oncol. 2013;6:528–38.CrossRefPubMedPubMedCentral

19.

Banys M, Müller V, Melcher C, Aktas B, Kasimir-Bauer S, Hagenbeck C, et al. Circulating tumor cells in breast cancer. Clin Chim Acta Int J Clin Chem. 2013;423:39–45.CrossRef

20.

Lustberg MB, Balasubramanian P, Miller B, Garcia-Villa A, Deighan C, Wu Y, et al. Heterogeneous atypical cell populations are present in blood of metastatic breast cancer patients. Breast Cancer Res. 2014;16:R23.CrossRefPubMedPubMedCentral

21.

Barriere G, Fici P, Gallerani G, Fabbri F, Zoli W, Rigaud M. Circulating tumor cells and epithelial, mesenchymal and stemness markers: characterization of cell subpopulations. Ann Transl Med. 2014;2:109.PubMedPubMedCentral

22.

Grover PK, Cummins AG, Price TJ, Roberts-Thomson IC, Hardingham JE. Circulating tumour cells: the evolving concept and the inadequacy of their enrichment by EpCAM-based methodology for basic and clinical cancer research. Ann Oncol Off J Eur Soc Med Oncol ESMO. 2014;25:1506–16.CrossRef

23.

Friedlander TW, Premasekharan G, Paris PL. Looking back, to the future of circulating tumor cells. Pharmacol Ther. 2014;142:271–80.CrossRefPubMed

24.

Yu M, Bardia A, Wittner BS, Stott SL, Smas ME, Ting DT, et al. Circulating breast tumor cells exhibit dynamic changes in epithelial and mesenchymal composition. Science. 2013;339:580–4.CrossRefPubMedPubMedCentral

25.

Martowicz A, Spizzo G, Gastl G, Untergasser G. Phenotype-dependent effects of EpCAM expression on growth and invasion of human breast cancer cell lines. BMC Cancer. 2012;12:501.CrossRefPubMedPubMedCentral

26.

Gostner JM, Fong D, Wrulich OA, Lehne F, Zitt M, Hermann M, et al. Effects of EpCAM overexpression on human breast cancer cell lines. BMC Cancer. 2011;11:45.CrossRefPubMedPubMedCentral

27.

Silva JM, Dominguez G, Silva J, Garcia JM, Sanchez A, Rodriguez O, et al. Detection of epithelial messenger RNA in the plasma of breast cancer patients is associated with poor prognosis tumor characteristics. Clin Cancer Res Off J Am Assoc Cancer Res. 2001;7:2821–5.

28.

Ignatiadis M, Kallergi G, Ntoulia M, Perraki M, Apostolaki S, Kafousi M, et al. Prognostic value of the molecular detection of circulating tumor cells using a multimarker reverse transcription-PCR assay for cytokeratin 19, mammaglobin A, and HER2 in early breast cancer. Clin Cancer Res Off J Am Assoc Cancer Res. 2008;14:2593–600.CrossRef

29.

Kufe DW. MUC1-C oncoprotein as a target in breast cancer: activation of signaling pathways and therapeutic approaches. Oncogene. 2013;32:1073–81.CrossRefPubMed

30.

Li G, Zhang J, Jin K, He K, Wang H, Lu H, et al. Human mammaglobin: a superior marker for reverse-transcriptase PCR in detecting circulating tumor cells in breast cancer patients. Biomark Med. 2011;5:249–60.CrossRefPubMed

31.

Iqbal N, Iqbal N. Human epidermal growth factor receptor 2 (HER2) in cancers: overexpression and therapeutic implications. Mol Biol Int. 2014;2014:852748.CrossRefPubMedPubMedCentral

32.

Turner N, Pestrin M, Galardi F, De Luca F, Malorni L, Di Leo A. Can biomarker assessment on circulating tumor cells help direct therapy in metastatic breast cancer? Cancers. 2014;6:684–707.CrossRefPubMedPubMedCentral

33.

Cristofanilli M, Budd GT, Ellis MJ, Stopeck A, Matera J, Miller MC, et al. Circulating tumor cells, disease progression, and survival in metastatic breast cancer. N Engl J Med. 2004;351:781–91.CrossRefPubMed

34.

Nolé F, Munzone E, Zorzino L, Minchella I, Salvatici M, Botteri E, et al. Variation of circulating tumor cell levels during treatment of metastatic breast cancer: prognostic and therapeutic implications. Ann Oncol Off J Eur Soc Med Oncol ESMO. 2008;19:891–7.CrossRef

35.

Dawood S, Broglio K, Valero V, Reuben J, Handy B, Islam R, et al. Circulating tumor cells in metastatic breast cancer: from prognostic stratification to modification of the staging system? Cancer. 2008;113:2422–30.CrossRefPubMed

36.

Zhang L, Riethdorf S, Wu G, Wang T, Yang K, Peng G, et al. Meta-analysis of the prognostic value of circulating tumor cells in breast cancer. Clin Cancer Res Off J Am Assoc Cancer Res. 2012;18:5701–10.CrossRef

37.

Bidard F-C, Peeters DJ, Fehm T, Nolé F, Gisbert-Criado R, Mavroudis D, et al. Clinical validity of circulating tumour cells in patients with metastatic breast cancer: a pooled analysis of individual patient data. Lancet Oncol. 2014;15:406–14.CrossRefPubMed

38.

Giordano A, Giuliano M, De Laurentiis M, Arpino G, Jackson S, Handy BC, et al. Circulating tumor cells in immunohistochemical subtypes of metastatic breast cancer: lack of prediction in HER2-positive disease treated with targeted therapy. Ann Oncol Off J Eur Soc Med Oncol ESMO. 2012;23:1144–50.CrossRef

39.

Giuliano M, Giordano A, Jackson S, Hess KR, De Giorgi U, Mego M, et al. Circulating tumor cells as prognostic and predictive markers in metastatic breast cancer patients receiving first-line systemic treatment. Breast Cancer Res. 2011;13:R67.CrossRefPubMedPubMedCentral

40.

Martín M, Custodio S, de Las Casas M-LM, García-Sáenz J-Á, de la Torre J-C, Bellón-Cano J-M, et al. Circulating tumor cells following first chemotherapy cycle: an early and strong predictor of outcome in patients with metastatic breast cancer. Oncologist. 2013;18:917–23.CrossRefPubMedPubMedCentral

41.

Budd GT, Cristofanilli M, Ellis MJ, Stopeck A, Borden E, Miller MC, et al. Circulating tumor cells versus imaging–predicting overall survival in metastatic breast cancer. Clin Cancer Res Off J Am Assoc Cancer Res. 2006;12:6403–9.CrossRef

42.

Smerage JB, Barlow WE, Hortobagyi GN, Winer EP, Leyland-Jones B, Srkalovic G, et al. Circulating tumor cells and response to chemotherapy in metastatic breast cancer: SWOG S0500. J Clin Oncol Off J Am Soc Clin Oncol. 2014;32:3483–9.CrossRef

43.

Bidard F-C, Fehm T, Ignatiadis M, Smerage JB, Alix-Panabières C, Janni W, et al. Clinical application of circulating tumor cells in breast cancer: overview of the current interventional trials. Cancer Metastasis Rev. 2013;32:179–88.CrossRefPubMed

44.

Lucci A, Hall CS, Lodhi AK, Bhattacharyya A, Anderson AE, Xiao L, et al. Circulating tumour cells in non-metastatic breast cancer: a prospective study. Lancet Oncol. 2012;13:688–95.CrossRefPubMed

45.

Riethdorf S, Müller V, Zhang L, Rau T, Loibl S, Komor M, et al. Detection and HER2 expression of circulating tumor cells: prospective monitoring in breast cancer patients treated in the neoadjuvant GeparQuattro trial. Clin Cancer Res Off J Am Assoc Cancer Res. 2010;16:2634–45.CrossRef

46.

Sandri MT, Zorzino L, Cassatella MC, Bassi F, Luini A, Casadio C, et al. Changes in circulating tumor cell detection in patients with localized breast cancer before and after surgery. Ann Surg Oncol. 2010;17:1539–45.CrossRefPubMed

47.

Bidard F-C, Mathiot C, Delaloge S, Brain E, Giachetti S, de Cremoux P, et al. Single circulating tumor cell detection and overall survival in nonmetastatic breast cancer. Ann Oncol Off J Eur Soc Med Oncol ESMO. 2010;21:729–33.CrossRef

48.

Biggers B, Knox S, Grant M, Kuhn J, Nemunatitis J, Fisher T, et al. Circulating tumor cells in patients undergoing surgery for primary breast cancer: preliminary results of a pilot study. Ann Surg Oncol. 2009;16:969–71.CrossRefPubMed

49.

Rack B, Schindlbeck C, Jückstock J, Andergassen U, Hepp P, Zwingers T, et al. Circulating tumor cells predict survival in early average-to-high risk breast cancer patients. J Natl Cancer Inst. 2014;106:dju066.CrossRefPubMedPubMedCentral

50.

Symmans WF, Peintinger F, Hatzis C, Rajan R, Kuerer H, Valero V, et al. Measurement of residual breast cancer burden to predict survival after neoadjuvant chemotherapy. J Clin Oncol Off J Am Soc Clin Oncol. 2007;25:4414–22.CrossRef

51.

Pierga J-Y, Petit T, Lévy C, Ferrero J-M, Campone M, Gligorov J, et al. Pathological response and circulating tumor cell count identifies treated HER2+ inflammatory breast cancer patients with excellent prognosis: BEVERLY-2 survival data. Clin Cancer Res Off J Am Assoc Cancer Res. 2015;21:1298–304.CrossRef

52.

Pierga J-Y, Bidard F-C, Mathiot C, Brain E, Delaloge S, Giachetti S, et al. Circulating tumor cell detection predicts early metastatic relapse after neoadjuvant chemotherapy in large operable and locally advanced breast cancer in a phase II randomized trial. Clin Cancer Res Off J Am Assoc Cancer Res. 2008;14:7004–10.CrossRef

53.

Meng S, Tripathy D, Shete S, Ashfaq R, Haley B, Perkins S, et al. HER-2 gene amplification can be acquired as breast cancer progresses. Proc Natl Acad Sci USA. 2004;101:9393–8.CrossRefPubMedPubMedCentral

54.

Georgoulias V, Bozionelou V, Agelaki S, Perraki M, Apostolaki S, Kallergi G, et al. Trastuzumab decreases the incidence of clinical relapses in patients with early breast cancer presenting chemotherapy-resistant CK-19mRNA-positive circulating tumor cells: results of a randomized phase II study. Ann Oncol Off J Eur Soc Med Oncol ESMO. 2012;23:1744–50.CrossRef

55.

Pusztai L, Viale G, Kelly CM, Hudis CA. Estrogen and HER-2 receptor discordance between primary breast cancer and metastasis. Oncologist. 2010;15:1164–8.CrossRefPubMedPubMedCentral

56.

Smerage JB, Hayes DF. The measurement and therapeutic implications of circulating tumour cells in breast cancer. Br J Cancer. 2006;94:8–12.CrossRefPubMedPubMedCentral

57.

Chambers AF, Naumov GN, Vantyghem SA, Tuck AB. Molecular biology of breast cancer metastasis. Clinical implications of experimental studies on metastatic inefficiency. Breast Cancer Res. 2000;2:400–7.CrossRefPubMedPubMedCentral

58.

Kalluri R, Weinberg RA. The basics of epithelial–mesenchymal transition. J Clin Invest. 2009;119:1420–8.CrossRefPubMedPubMedCentral

59.

Powell AA, Talasaz AH, Zhang H, Coram MA, Reddy A, Deng G, et al. Single cell profiling of circulating tumor cells: transcriptional heterogeneity and diversity from breast cancer cell lines. PLoS ONE. 2012;7:e33788.CrossRefPubMedPubMedCentral

60.

Wolff AC, Hammond MEH, Hicks DG, Dowsett M, McShane LM, Allison KH, et al. Recommendations for human epidermal growth factor receptor 2 testing in breast cancer: American Society of Clinical Oncology/College of American Pathologists clinical practice guideline update. J Clin Oncol Off J Am Soc Clin Oncol. 2013;31:3997–4013.CrossRef

Titel: Review: circulating tumor cells in the practice of breast cancer oncology
verfasst von: R. Ramos-Medina
F. Moreno
S. Lopez-Tarruella
M. del Monte-Millán
I. Márquez-Rodas
E. Durán
Y. Jerez
J. A. Garcia-Saenz
I. Ocaña
S. Andrés
T. Massarrah
M. González-Rivera
M. Martin
Publikationsdatum: 08.12.2015
Verlag: Springer International Publishing
Erschienen in: Clinical and Translational Oncology / Ausgabe 8/2016
Print ISSN: 1699-048X
Elektronische ISSN: 1699-3055
DOI: https://doi.org/10.1007/s12094-015-1460-2

Neu im Fachgebiet Onkologie

10.04.2024 | PSA-Screening | Nachrichten

Springer Medizin

Review: circulating tumor cells in the practice of breast cancer oncology

Abstract

Neu im Fachgebiet Onkologie

Einladung zum PSA-Screening senkt die Krebssterblichkeit

Chemotherapie mit Hindernissen

Das Ende der vollständigen axillären Lymphknotendissektion

Senkt Schlafapnoe das Überleben bei Lungenkrebs?

Update Onkologie

Springer Medizin

Abstract

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 8/2016

Expression of serum miR-218 in hepatocellular carcinoma and its prognostic significance

ATAD2 is overexpressed in gastric cancer and serves as an independent poor prognostic biomarker

CA125-related tumor cell kinetics variables after chemotherapy in advanced ovarian cancer: a systematic review

Doublet BRAF/MEK inhibition versus single-agent BRAF inhibition in the management of BRAF-mutant advanced melanoma, biological rationale and meta-analysis of published data

GEINOFOTE: efficacy and safety of fotemustine in patients with high-grade recurrent gliomas and poor performance status

Late recurrence (more than 10 years) in early (tumors equal to or smaller than 2 cm) breast cancer patients

Neu im Fachgebiet Onkologie

Einladung zum PSA-Screening senkt die Krebssterblichkeit

Chemotherapie mit Hindernissen

Das Ende der vollständigen axillären Lymphknotendissektion

Senkt Schlafapnoe das Überleben bei Lungenkrebs?

Update Onkologie